NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.

NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.